Su Qi-jian, Li Yi-zhong, Liang Fei-li, Xiao Jian, Deng Xin
Center for AIDS Research, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, Guangxi, PR China.
Int J STD AIDS. 2014 Jan;25(1):24-8. doi: 10.1177/0956462413496771. Epub 2013 Jul 19.
We conducted a study to determine whether an immunomodulator, polyactin A, is able to enhance the immunologic response in patients with insufficient immunologic response to highly active antiretroviral therapy. From 783 patients, 48 were eligible and were randomly assigned to an experimental group receiving polyactin A for 3 months or a control group. CD4(+) T-cell counts in the experimental group increased from 201 ± 31 to 228 ± 38 cells/µl after treatment (p < 0.001). CD4(+) T-cell counts in the control group and CD8(+) T-cell counts and CD4(+)/CD8(+) ratios in both groups did not differ significantly between baseline and month 3. The experimental group had a higher CD4(+) T-cell count than the control group at month 3 (228 ± 38 versus 205 ± 35, p < 0.05). Our work demonstrated that polyactin A can increase CD4(+) T-cell counts in patients with insufficient immunologic response to highly active antiretroviral therapy, but further studies are required to determine its clinical benefits.
我们开展了一项研究，以确定一种免疫调节剂聚肌胞是否能够增强对高效抗逆转录病毒疗法免疫反应不足的患者的免疫应答。在783例患者中，48例符合条件，并被随机分配至接受聚肌胞治疗3个月的试验组或对照组。治疗后，试验组的CD4(+) T细胞计数从201±31升至228±38个细胞/微升（p<0.001）。对照组的CD4(+) T细胞计数以及两组的CD8(+) T细胞计数和CD4(+)/CD8(+)比值在基线和第3个月之间无显著差异。在第3个月时，试验组的CD4(+) T细胞计数高于对照组（228±38对205±35，p<0.05）。我们的研究表明，聚肌胞可增加对高效抗逆转录病毒疗法免疫反应不足患者的CD4(+) T细胞计数，但还需要进一步研究以确定其临床益处。
